May 02, 2011 | by Actelion Pharmaceuticals Ltd
|
Reading time: 1 minute
May 02, 2011, Actelion (SIX: ATLN) announced that it has taken note of a letter in which one of its major shareholders criticizes the handling of - among others - disclosure and other reporting requirements in relation to ongoing litigation in the United States. Respectfully, the company believes that these criticisms have no factual basis.
This letter was issued ahead of the final jury deliberations in the ongoing litigation in the United States (Asahi Kasei Pharma Corp. v. Actelion Ltd., case number CIV 478533, Superior Court of the State of California, County of San Mateo). On Friday, the jury awarded Asahi up to USD 547 million. On Tuesday, the jury will continue deliberations regarding potential punitive awards.
The company is disappointed, but respectful of the jury`s verdict in this ongoing litigation. Once the jury has concluded their deliberations, Actelion will decide on potential further steps, including (but not limited to) an appeal.
Also after jury deliberations have concluded, Actelion will be in a position to address the criticisms made in the letter.
Contact
Roland Haefeli Vice President, Head of Investor Relations & Public Affairs Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 +1 650 624 69 36 www.actelion.com
Editor's note: Image rights belong to the respective publisher.
Conclusion of this article: « Actelion Statement on Letter by one of its Shareholders »
Source: Actelion Pharmaceuticals Ltd, Press release